Vetoquinol SA
PAR:VETO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
78.3
109
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VETO stock under the Base Case scenario is 86.78 EUR. Compared to the current market price of 79.3 EUR, Vetoquinol SA is Undervalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vetoquinol SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VETO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vetoquinol SA
Balance Sheet Decomposition
Vetoquinol SA
Current Assets | 383.5m |
Cash & Short-Term Investments | 162.8m |
Receivables | 96.3m |
Other Current Assets | 124.3m |
Non-Current Assets | 323m |
Long-Term Investments | 1.6m |
PP&E | 87.6m |
Intangibles | 223.7m |
Other Non-Current Assets | 10m |
Current Liabilities | 138.8m |
Accounts Payable | 118.6m |
Other Current Liabilities | 20.2m |
Non-Current Liabilities | 24.6m |
Long-Term Debt | 9.7m |
Other Non-Current Liabilities | 14.9m |
Earnings Waterfall
Vetoquinol SA
Revenue
|
537.5m
EUR
|
Cost of Revenue
|
-275.1m
EUR
|
Gross Profit
|
262.3m
EUR
|
Operating Expenses
|
-197.6m
EUR
|
Operating Income
|
64.7m
EUR
|
Other Expenses
|
-17.6m
EUR
|
Net Income
|
47.1m
EUR
|
Free Cash Flow Analysis
Vetoquinol SA
EUR | |
Free Cash Flow | EUR |
VETO Profitability Score
Profitability Due Diligence
Vetoquinol SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Vetoquinol SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
VETO Solvency Score
Solvency Due Diligence
Vetoquinol SA's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
Vetoquinol SA's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VETO Price Targets Summary
Vetoquinol SA
According to Wall Street analysts, the average 1-year price target for VETO is 100.98 EUR with a low forecast of 86.86 EUR and a high forecast of 126 EUR.
Dividends
Current shareholder yield for VETO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VETO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
Contact
IPO
Employees
Officers
The intrinsic value of one VETO stock under the Base Case scenario is 86.78 EUR.
Compared to the current market price of 79.3 EUR, Vetoquinol SA is Undervalued by 9%.